The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

The comedian stunned fans with a leggy Valentino mini dress as she shared candid snaps and opened up about her wellness ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

The Delhi High Court ruled against Novo Nordisk's request to block Dr Reddy's production of semaglutide for export. The case ...

A WOMAN has left people with their jaws on the floor after sharing her epic Mounjaro weight loss journey. Mum Lisa jumped on ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...